The groundbreaking therapy of tirzepatide peptide represents a exciting breakthrough in the management of diabetes mellitus type 2. Distinct from existing therapies, tirzepatide targets dual pathways – glucagon-like peptide-1 (GLP-1) and the GIP hormone – resulting in improved glucose regulation and